BAUDETTE, Minn., Aug. 1, 2018 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plansto release its second quarter and year-to-date 2018 financial results on Tuesday, August 7, 2018, before the opening of the U.S. financial markets. The earnings press release will be accessible through the Investor Relations
Arthur S. Przybyl, President and Chief Executive Officer, and Stephen P. Carey, Vice President, Finance, and Chief Financial Officer, also plan to host a conference call to review those results starting at 10:30am Eastern Time on Tuesday, August 7, 2018. The call will be open to the public and can be accessed through a conference line by dialing (866) 776-8875. The conference ID is 9878939.
A recording of the conference call will be available within two hours of the completion of the call and will remain accessible for a period of seven days following the call. To access the replay, dial (800) 585-8367. The access code for the replay is 9878939.
ANI Pharmaceuticals, Inc. (the "Company" or "ANI") is an integrated specialty pharmaceutical company focused on delivering value to our customers by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceuticals. The Company's targeted areas of product development currently include controlled substances, oncolytics (anti-cancers), hormones and steroids, and complex formulations involving extended release and combination products. For more information, please visit our website www.anipharmaceuticals.com.
For more information about ANI, please contact:Investor RelationsIR@anipharmaceuticals.com
View original content:http://www.prnewswire.com/news-releases/ani-pharmaceuticals-schedules-conference-call-to-discuss-second-quarter-and-year-to-date-2018-financial-results-300689758.html
SOURCE ANI Pharmaceuticals, Inc.
Subscribe to our Free Newsletters!
Collagen plays a crucial role in glowing skin, strong nails and shiny hair. You can boost collagen ...
CRISPR technology is a simple but potent tool for editing any part of the genome (complete set of ...
FDA recently approved Mogamulizumab-kpkc, a human monoclonal antibody prescribed for adult ...View All